- Home
- KZIA vs FTEL Comparison
KZIA vs FTEL Comparison
Compare KZIA & FTEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- FTEL
- Stock Information
- Founded
- KZIA 1994
- FTEL 2007
- Country
- KZIA Australia
- FTEL Australia
- Employees
- KZIA N/A
- FTEL N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- FTEL
- Sector
- KZIA Health Care
- FTEL
- Exchange
- KZIA Nasdaq
- FTEL Nasdaq
- Market Cap
- KZIA 9.0M
- FTEL 9.8M
- IPO Year
- KZIA 1999
- FTEL 2023
- Fundamental
- Price
- KZIA $8.04
- FTEL $0.47
- Analyst Decision
- KZIA Strong Buy
- FTEL
- Analyst Count
- KZIA 2
- FTEL 0
- Target Price
- KZIA $14.00
- FTEL N/A
- AVG Volume (30 Days)
- KZIA 17.4K
- FTEL 63.4K
- Earning Date
- KZIA 06-05-2025
- FTEL 04-28-2025
- Dividend Yield
- KZIA N/A
- FTEL N/A
- EPS Growth
- KZIA N/A
- FTEL N/A
- EPS
- KZIA N/A
- FTEL N/A
- Revenue
- KZIA $1,549,158.00
- FTEL $4,990,695.00
- Revenue This Year
- KZIA N/A
- FTEL N/A
- Revenue Next Year
- KZIA $49.25
- FTEL N/A
- P/E Ratio
- KZIA N/A
- FTEL N/A
- Revenue Growth
- KZIA 248983.08
- FTEL 29.02
- 52 Week Low
- KZIA $2.86
- FTEL $0.36
- 52 Week High
- KZIA $39.05
- FTEL $49.50
- Technical
- Relative Strength Index (RSI)
- KZIA 50.26
- FTEL 43.17
- Support Level
- KZIA $7.52
- FTEL $0.44
- Resistance Level
- KZIA $8.33
- FTEL $0.51
- Average True Range (ATR)
- KZIA 0.62
- FTEL 0.04
- MACD
- KZIA 0.04
- FTEL 0.00
- Stochastic Oscillator
- KZIA 67.93
- FTEL 27.42
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About FTEL Fitell Corporation
Fitell Corp engages in primary operations of selling gym and fitness equipment in Australia through its indirectly held wholly owned subsidiaries. It operates in two segments: online fitness equipment distribution and licensing business to service the large and growing boutique fitness sector of the broader health and fitness club industry. The majority fitness equipment business is conducted in Australia via its own e-commerce platform and, through third-party sites. Licensing service offers a turnkey solution for personal training studios and commercial gym chains. The company earns maximum of revenue for retail.